Skip to main content
OpenTrials

Clinical trial condition

Mantle Cell Lymphoma

Explore clinical trials studying Mantle Cell Lymphoma. Study availability and eligibility vary by location and protocol.

252 public trials 59 recruiting studies
Refine in advanced search Browse all conditions

Mantle Cell Lymphoma trial results

Completed

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

NCT00963534

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Århus University Hospital Aarhus, Denmark
  • Herlev Hospital Copenhagen, Denmark
  • Rigshospitalet, Department of Hematology Copenhagen, Denmark
  • Helsinki University Central Hospital Helsinki, Finland
View all 17 locations
View Trial Details
Completed

Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL

NCT01737177

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • UOC Ematologia Trani Trani, Barletta-Andria-Trani (BT), Italy
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST Meldola Meldola, Forlì Cesena, Italy
  • Ematologia Istituto Clinico Humanitas Rozzano, Milano, Italy
  • Centro di riferimento Oncologico CRO Aviano Aviano, Pordenone, Italy
View all 43 locations
View Trial Details
Completed

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

NCT00877006

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Teva Investigational Site 165 Tucson, Arizona, United States
  • Teva Investigational Site 167 Little Rock, Arkansas, United States
  • Teva Investigational Site 11 Corona, California, United States
  • Teva Investigational Site 21 Fountain Valley, California, United States
View all 128 locations
View Trial Details
Completed

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

NCT01460134

Conditions
Adenocarcinoma, Adnexal Diseases, Any T-cell Malignancy, +70 more
Locations
  • Mayo Clinic Arizona - Cancer Clinical Research Unit Scottsdale, Arizona, United States
  • Stanford Cancer Center - Stanford University Stanford, California, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine New York, United States
View Trial Details
Completed

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

NCT02142530

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Diffuse Large B-cell Lymphoma, +27 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth-Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

NCT01562977

Conditions
Aggressive Lymphoma, Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, +12 more
Locations
  • Hospital Germans Trias i Pujol Badalona, Barcelona, Spain
  • Hospital Duran i Reynals Sabadell, Barcelona, Spain
  • Hospital SAS de Jerez Jerez de la Frontera, Cádiz, Spain
  • Hospital Dr. Jose Molina Orosa Arrecife, Lanzarote, Spain
View all 28 locations
View Trial Details
Completed

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

NCT01399840

Conditions
Acute Myeloid Leukemia, Bone Marrow Diseases, Chronic Disease, +24 more
Locations
  • Indiana University Simon Cancer Center Indianapolis, Indiana, United States
  • Seattle Cancer Care Alliance Seattle, Washington, United States
  • University of Wisconsin Madison, Wisconsin, United States
  • University College London London, United Kingdom
View Trial Details
Completed

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

NCT00472420

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • National Institute of Oncology, A Dept of Internal Medicine Budapest, Hungary
  • University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology Debrecen, Hungary
  • Petz Aladar Megyei Korhaz; Hematologia Győr, Hungary
  • Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology Kaposvár, Hungary
View Trial Details

Related conditions